Celgene Presents First Results Of New Data Of Abraxane, Atezolizumab Combination

Celgene Corp. (CELG) on Monday announced the first results from the IMpassion130 study evaluating Abraxane, or paclitaxel protein-bound particles for injectable suspension (albumin-bound) in combination with atezolizumab ,or Tecentriq, in patients with first-line locally advanced triple negative breast cancer (TNBC).

from RTT - Biotech https://ift.tt/2S9gtSE
via IFTTT